107 related articles for article (PubMed ID: 21748639)
1. Five-step process for screening antisense compounds for efficacy: gene target IL-12Rb2.
Marshall NB; Hauck LL; Mourich DV
Methods Mol Biol; 2011; 764():153-68. PubMed ID: 21748639
[TBL] [Abstract][Full Text] [Related]
2. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.
Marshall NB; Oda SK; London CA; Moulton HM; Iversen PL; Kerkvliet NI; Mourich DV
J Immunol Methods; 2007 Aug; 325(1-2):114-26. PubMed ID: 17673254
[TBL] [Abstract][Full Text] [Related]
3. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.
Nelson MH; Stein DA; Kroeker AD; Hatlevig SA; Iversen PL; Moulton HM
Bioconjug Chem; 2005; 16(4):959-66. PubMed ID: 16029037
[TBL] [Abstract][Full Text] [Related]
4. Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.
Deere J; Iversen P; Geller BL
Antimicrob Agents Chemother; 2005 Jan; 49(1):249-55. PubMed ID: 15616302
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.
Moulton HM; Nelson MH; Hatlevig SA; Reddy MT; Iversen PL
Bioconjug Chem; 2004; 15(2):290-9. PubMed ID: 15025524
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
[TBL] [Abstract][Full Text] [Related]
7. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.
Moulton HM; Fletcher S; Neuman BW; McClorey G; Stein DA; Abes S; Wilton SD; Buchmeier MJ; Lebleu B; Iversen PL
Biochem Soc Trans; 2007 Aug; 35(Pt 4):826-8. PubMed ID: 17635157
[TBL] [Abstract][Full Text] [Related]
8. Cell-penetrating peptides-based strategies for the delivery of splice redirecting antisense oligonucleotides.
El Andaloussi S; Said Hassane F; Boisguerin P; Sillard R; Langel U; Lebleu B
Methods Mol Biol; 2011; 764():75-89. PubMed ID: 21748634
[TBL] [Abstract][Full Text] [Related]
9. Improved cellular uptake of antisense peptide nucleic acids by conjugation to a cell-penetrating peptide and a lipid domain.
Shiraishi T; Nielsen PE
Methods Mol Biol; 2011; 751():209-21. PubMed ID: 21674333
[TBL] [Abstract][Full Text] [Related]
10. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cellular delivery of cell-penetrating peptide-peptide nucleic acid conjugates by photochemical internalization.
Shiraishi T; Nielsen PE
Methods Mol Biol; 2011; 683():391-7. PubMed ID: 21053145
[TBL] [Abstract][Full Text] [Related]
12. Modification of pre-mRNA splicing by antisense oligonucleotides.
Kole R
Acta Biochim Pol; 1997; 44(2):231-7. PubMed ID: 9360712
[TBL] [Abstract][Full Text] [Related]
13. Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis.
Geller BL; Deere J; Tilley L; Iversen PL
J Antimicrob Chemother; 2005 Jun; 55(6):983-8. PubMed ID: 15872045
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
Amantana A; Iversen PL
Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
[TBL] [Abstract][Full Text] [Related]
15. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.
Davis RL; Homer VM; George PM; Brennan SO
Hum Mutat; 2009 Feb; 30(2):221-7. PubMed ID: 18853456
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC; Jiang XP; Elliott RL; Head JF
Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
[TBL] [Abstract][Full Text] [Related]
17. Correction of aberrant pre-mRNA splicing by antisense oligonucleotides in beta-thalassemia Egyptian patients with IVSI-110 mutation.
El-Beshlawy A; Mostafa A; Youssry I; Gabr H; Mansour IM; El-Tablawy M; Aziz M; Hussein IR
J Pediatr Hematol Oncol; 2008 Apr; 30(4):281-4. PubMed ID: 18391696
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
Popplewell LJ; Graham IR; Malerba A; Dickson G
Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
[TBL] [Abstract][Full Text] [Related]
19. Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.
Tilley LD; Mellbye BL; Puckett SE; Iversen PL; Geller BL
J Antimicrob Chemother; 2007 Jan; 59(1):66-73. PubMed ID: 17079242
[TBL] [Abstract][Full Text] [Related]
20. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
